Assignee
RHIZEN PHARMACEUTICALS SA
CH·43 granted patents·13 pending applications·119 citations·filing 2010–2021
Top patents by PatentIndex Score
56 records- 0197US9150579B2Selective PI3K delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2013·Granted Oct 6, 2015·34 cites·14 claims
- 0296US9475818B2Selective PI3K delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2015·Granted Oct 25, 2016·17 cites·20 claims
- 0394US10072013B2Selective PI3K delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2017·Granted Sep 11, 2018·9 cites·20 claims
- 0494US9669033B2Selective PI3K delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2016·Granted Jun 6, 2017·10 cites·15 claims
- 0593US8921364B2Modulators of calcium release-activated calcium channelRHIZEN PHARMACEUTICALS SA·Filed 2012·Granted Dec 30, 2014·7 cites·23 claims
- 0692US8377970B2Modulators of calcium release-activated calcium channelRHIZEN PHARMACEUTICALS SA·Filed 2010·Granted Feb 19, 2013·7 cites·28 claims
- 0789US9018375B2Substituted chromenes as kinase modulatorsRHIZEN PHARMACEUTICALS SA·Filed 2013·Granted Apr 28, 2015·8 cites·5 claims
- 0888US10414773B2Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulationsRHIZEN PHARMACEUTICALS SA·Filed 2018·Granted Sep 17, 2019·1 cites·28 claims
- 0987US9969740B2Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulationsRHIZEN PHARMACEUTICALS SA·Filed 2015·Granted May 15, 2018·2 cites·29 claims
- 1085US10981919B2Selective PI3K delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2020·Granted Apr 20, 2021·1 cites·13 claims
- 1185US10570142B2Selective PI3K delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2018·Granted Feb 25, 2020·2 cites·29 claims
- 1285US9421209B2Kinase modulatorsRHIZEN PHARMACEUTICALS SA·Filed 2015·Granted Aug 23, 2016·3 cites·13 claims
- 1383US9815831B23,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2013·Granted Nov 14, 2017·5 cites·32 claims
- 1483US9737521B2Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitorRHIZEN PHARMACEUTICALS SA·Filed 2013·Granted Aug 22, 2017·4 cites·21 claims
- 1581US10220035B2Compounds as modulators of protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2015·Granted Mar 5, 2019·2 cites·12 claims
- 1680US9783533B2Glutaminase inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2015·Granted Oct 10, 2017·4 cites·13 claims
- 1780US9758514B2Modulators of calcium release-activated calcium channelRHIZEN PHARMACEUTICALS SA·Filed 2014·Granted Sep 12, 2017·1 cites·47 claims
- 1878US11858907B2Kinase modulatorsRHIZEN PHARMACEUTICALS SA·Filed 2019·Granted Jan 2, 2024·0 cites·18 claims
- 1976US2021403475A1Novel selective pi3k delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2021·Application pending·0 cites
- 2074US2021401840A1Novel compounds as modulators of protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2021·Application pending·0 cites
- 2171US9777018B2Compounds as modulators of GPR-119RHIZEN PHARMACEUTICALS SA·Filed 2015·Granted Oct 3, 2017·1 cites·36 claims
- 2270US11466006B2Dual selective PI3 delta and gamma kinase inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2020·Granted Oct 11, 2022·0 cites·10 claims
- 2370US11020399B2Intermediates useful in the synthesis of compounds as modulators of protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2019·Granted Jun 1, 2021·0 cites·2 claims
- 2470US9758474B2Immunomodulator and anti-inflammatory compoundsRHIZEN PHARMACEUTICALS SA·Filed 2014·Granted Sep 12, 2017·1 cites·8 claims
- 2569US10947244B2Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulationsRHIZEN PHARMACEUTICALS SA·Filed 2019·Granted Mar 16, 2021·0 cites·40 claims
- 2669US10668051B2Modulators of calcium release-activated calcium channelRHIZEN PHARMACEUTICALS SA·Filed 2019·Granted Jun 2, 2020·0 cites·20 claims
- 2769US10246450B2Modulators of calcium release-activated calcium channelRHIZEN PHARMACEUTICALS SA·Filed 2018·Granted Apr 2, 2019·0 cites·19 claims
- 2869US2021269446A1Forms of a pi3k delta selective inhibitor for use in pharmaceutical formulationsRHIZEN PHARMACEUTICALS SA·Filed 2020·Application pending·0 cites
- 2968US2021371416A1Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2021·Application pending·0 cites
- 3067US11065236B2Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitorRHIZEN PHARMACEUTICALS SA·Filed 2019·Granted Jul 20, 2021·0 cites·13 claims
- 3167US9944631B2Modulators of calcium release-activated calcium channelRHIZEN PHARMACEUTICALS SA·Filed 2017·Granted Apr 17, 2018·0 cites·15 claims
- 3266US2020199133A1Selective dual inhibitors of pi3 delta and gamma protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2020·Application pending·0 cites
- 3364US10413532B2Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitorRHIZEN PHARMACEUTICALS SA·Filed 2018·Granted Sep 17, 2019·0 cites·14 claims
- 3464US2021032236A1Novel glutaminase inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2020·Application pending·0 cites
- 3563US10538501B2Kinase modulatorsRHIZEN PHARMACEUTICALS SA·Filed 2016·Granted Jan 21, 2020·0 cites·22 claims
- 3663US10058539B2Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitorRHIZEN PHARMACEUTICALS SA·Filed 2017·Granted Aug 28, 2018·0 cites·33 claims
- 3762US9790224B2Dual selective PI3 delta and gamma kinase inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2014·Granted Oct 17, 2017·0 cites·32 claims
- 3861US10851107B2Dual selective P13 delta and gamma kinase inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2017·Granted Dec 1, 2020·0 cites·23 claims
- 3961US10611759B2Glutaminase inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2017·Granted Apr 7, 2020·0 cites·25 claims
- 4061US10322130B2Substituted chromenones as modulators of protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2017·Granted Jun 18, 2019·0 cites·35 claims
- 4161US10179786B2Selective dual inhibitors of PI3 delta and gamma protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2017·Granted Jan 15, 2019·0 cites·5 claims
- 4261US2019202836A1Selective dual inhibitors of pi3 delta and gamma protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2018·Application pending·0 cites
- 4358US2021030757A1Method of treatment and compositions comprising a dual p13k delta-gamma kinase inhibitor and a corticosteroidRHIZEN PHARMACEUTICALS SA·Filed 2020·Application pending·0 cites
- 4457US9708329B2Selective dual inhibitors of PI3 delta and gamma protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2015·Granted Jul 18, 2017·0 cites·10 claims
- 4556US11478481B2Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticalsRHIZEN PHARMACEUTICALS SA·Filed 2018·Granted Oct 25, 2022·0 cites·5 claims
- 4655US11066402B23,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2017·Granted Jul 20, 2021·0 cites·19 claims
- 4754US10130635B2Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticalsRHIZEN PHARMACEUTICALS SA·Filed 2016·Granted Nov 20, 2018·0 cites·15 claims
- 4854US2019248791A1Novel modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancerRHIZEN PHARMACEUTICALS SA·Filed 2018·Application pending·0 cites
- 4954US2017342089A1Novel compounds as modulators of gpr-119RHIZEN PHARMACEUTICALS SA·Filed 2017·Application pending·0 cites
- 5052US2020289520A1Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphomaRHIZEN PHARMACEUTICALS SA·Filed 2018·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →